Clinical-stage biotechnology company developing engineered cyclodextrin-based therapeutics to remove toxic oxidized cholesterol, including 7-ketocholesterol, and address age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and age-related macular degeneration
Clinical-stage biotechnology company developing engineered cyclodextrin-based therapeutics to remove toxic oxidized cholesterol, including 7-ketocholesterol, and address age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and age-related macular degeneration. Its lead candidate UDP-003 has reported Phase 1 human data demonstrating mobilization and excretion of 7-ketocholesterol.